Ki-ras point mutation and p53 expression in human pancreatic cancer: A comparative study among Chinese, Japanese, and Western patients

Cancer Epidemiology Biomarkers and Prevention

Volumn 9, Issue 3, 2000, Pages 279-284

  Dong, Ming ^a,b   Nio, Yoshinori ^a   Tamura, Katsuhiro ^a   Song, Mao Min ^b   Guo, Ke Jian ^b   Guo, Ren Xuan ^b   Dong, Yu Ting ^b  

^a SHIMANE UNIVERSITY   (Japan)

^b CHINA MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; ASIAN; CHINESE; DISEASE ASSOCIATION; FEMALE; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; ONCOGENE RAS; PANCREAS CANCER; POINT MUTATION; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; CHINA; EUROPE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; GENES, RAS; HUMANS; IMMUNOHISTOCHEMISTRY; JAPAN; MALE; MIDDLE AGED; NORTH AMERICA; PANCREATIC NEOPLASMS; POINT MUTATION; PROGNOSIS;

EID: 0034102707     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Hruban, R. H., van Mansfeld, A. D., Offerhaus, G. J., van Weering, D. H., Allison, D. C., Goodman, S. N., Kensler, T. W., Bose, K. K., Cameron, J. L., and Bos, J. L. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am. J. Pathol., 143: 545-554, 1993.
2. Li, L. D., Zhang, S. W., Lu, F. Z., Mu, R., Sun, X. D., HuangFu, X. M., Sun, J., Zhou, Y. S., Xia, Y., Dai, X. D., Rao, K. Q., Chen, Y. D., Sun, A. M., and Xue, Z. F. The spectrum of death and classified constitution of malignant tumors in China (in Chinese). Chinese J. Oncol., 19: 323-328, 1997.
3. Pellegata, N. S., Sessa, F., Renault, B., Bonato, M., Leone, B. E., Solcia, E., and Ranzani, G. N. K-ras and p53 gene mutations in pancreatic cancer, ductal and nonductal tumors progress through different genetic lesions. Cancer Res., 54: 1556-1560, 1994.
4. Sugio, K., Gazdar, A. F., Albores-Saavedra, J., and Kokkinakis, D. M. High yields of K-ras mutations in intraductal papillary mucinous tumors and invasive adenocarcinomas induced by N-nitroso (2-hydroxypropyl) (2-oxopropyl) amine in the pancreas of female Syrian hamsters. Carcinogenesis (Lond.), 17: 303-309, 1996.
5. Grunewald, K., Lyons, J., Frohlich, A., Feichtinger, H., Weger, R. A., Schwab, G., Janssen, J. W., and Bartram, C. R. High frequency of Ki-ras codon 12 mutations in pancreatic adenocarcinomas. Int. J. Cancer, 43: 1037-1041, 1989.
6. Tada, M., Ohashi, M., Shiratori, Y., Okudaira, T., Komatsu, Y., Kawabe, T., Yoshida, H., Machinami, R., Kishi, K., and Omata, M. Analysis of K-ras gene mutation in hyperplastic duct cells of the pancreas without pancreatic disease. Gastroenterology, 110: 227-231, 1996.
7. van Es, J. M., Polak, M. M., van den Berg, F. M., Ramsoekh, T. B., Craanen, M. E., Hruban, R. H., and Offerhaus, G. J. Molecular markers for diagnostic cytology of neoplasms in the head region of the pancreas: mutation of K-ras and overexpression of the p53 protein product. J. Clin. Pathol., 48: 218-222, 1995.
8. Harada, N., Gansauge, S., Gansauge, F., Gause, H., Shimoyama, S., Imaizumi, T., Mattfeld, T., Schoenberg, M. H., and Beger, H. G. Nuclear accumulation of p53 correlates significantly with clinical features and inversely with the expression of the cyclin-dependent kinase inhibitor p21WAF1/CIP1 in pancreatic cancer. Brit. J. Cancer, 76: 299-305, 1997 .
9. Zambetti, G. P., Olson, D., Labow, M., and Levine, A. J. A mutant p53 protein is required for maintenance of the transformed phenotype in cells transformed with p53 plus ras cDNAs. Proc. Natl. Acad. Sci. USA, 89: 3952-3956, 1992.
10. Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Jr., Butel, J. S., and Bradley, A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature (Lond.), 356: 215-221, 1992.
11. Scarpa, A., Capelli, P., Villaneuva, A., Zamboni, G., Lluis, F., Accolla, R., Mariuzzi, G., and Capella, G. Pancreatic cancer in Europe: Ki-ras gene mutation pattern shows geographical differences. Int. J. Cancer, 57: 167-171, 1994.
12. Hoshi, T., Imai, M., and Ogawa, K. Frequent K-ras mutations and absence of p53 mutations in mucin-producing tumors of the pancreas. J. Surg. Oncol., 55: 84-94, 1994.
13. Dong, M., Nio, Y., Sato, Y., Tamura, K., Song, M. M., Tian, Y. L., and Dong, Y. T. Comparative study of p53 expression in primary invasive ductal carcinoma of the pancreas between Chinese and Japanese. Pancreas, 17: 229-237, 1998.
14. Mariyama, M., Kishi, K., Nakamura, K., Obata, H., and Nishimura, S. Frequency and types of point mutation at the 12th codon of the c-Ki-ras gene found in pancreatic cancers from Japanese patients. Jpn. J. Cancer Res., 80: 622-626, 1989.
15. Nagata, Y., Abe, M., Motoshima, K., Nakayama, E., and Shiku, H. Frequent glycine-to-aspartic acid mutations at codon 12 of c-Ki-ras gene in human pancreatic cancer in Japanese. Jpn. J. Cancer Res., 81: 135-140, 1990.
16. Song, M. M., Nio, Y., Sato, Y., Tamura, K., and Furuse, K. Clinicopathological significance of Ki-ras point mutation and p21 expression in benign and malignant exocrine tumors of the human pancreas. Int. J. Pancreatol., 20: 85-93, 1996.
17. Nio, Y., Dong, M., Uegaki, K., Hirahara, N., Minari, Y., Sasaki, S., Takamura, M., Iguchi, C., and Tamura, K. Comparative significance of p53 and WAF/1-p21 expression on the efficacy of adjuvant chemotherapy for resectable invasive ductal carcinoma of the pancreas. Pancreas, 18: 117-126, 1999.
18. Melhem, M. F., Law, J. C., el-Ashmawy, L., Johnson, J. T., Landreneau, R. L., Srivastava, S., and Whiteside, T. L. Assessment of sensitivity and specificity of immunohistochemical staining of p53 in lung and head and neck cancers. Am. J. Pathol., 146: 1170-1177, 1995.
19. Sobin, L. H., and Wittekind, Ch. TNM Classification of Malignant Tumours, 5th ed., pp. 87-90, New York: John Wiley and Sons, Inc., 1997.
20. Inoue, S., Nakao, A., Kasai, Y., Harada, A., Nonami, T., and Takagi, H. Detection of hepatic micrometastasis in pancreatic adenocarcinoma patients by two-stage polymerase chain reaction/restriction fragment length polymorphism analysis. Jpn. J. Cancer Res., 86: 626-630, 1995.
21. Motojima, K., Kohara, N., Furui, J., Terada, M., Tsunoda, T., Nagata, Y., and Urano, K. Detection of point mutation of Kirsten ras oncogene in pancreatic carcinoma by polymerase chain reaction (in Japanese). Nippon Geka Gakkai Zasshi, 92: 453-458, 1991.
22. Neuman, W. L., Wasylyshyn, M. L., Jacoby, R., Erroi, F., Angriman, I., Montag, A., Brasitus, T., Michelassi, F., and Westbrook, C. A. Evidence for a common molecular pathogenesis in colorectal, gastric, and pancreatic cancer. Genes Chromosomes Cancer, 3: 468-473, 1991.
23. Burmer, G. C., Rabinovitch, P. S., and Loeb, L. A. Frequency and spectrum of c-Ki-ras mutations in human sporadic colon carcinoma, carcinomas arising in ulcerative colitis, and pancreatic adenocarcinoma. Environ. Health Perspect., 93: 27-31, 1991.
24. Lemoine, N. R., Jain, S., Hughes, C. M., Staddon, S. L., Maillet, B., Hall, P. A., and Kloppel, G. Ki-ras oncogene activation in preinvasive pancreatic cancer. Gastroenterology, 102: 230-236, 1992.
25. Mulcahy, H. E., Lyautey, J., Lederrey, C., qi Chen, X., Anker, P., Alstead, E. M., Ballinger, A., Farthing, M. J., and Stroun, M. A prospective study of K-ras mutations in the plasma of pancreatic cancer patients. Clin. Cancer Res., 4: 271-275, 1998.
26. Berrozpe, G., Schaeffer, J., Peinado, M. A., Real, F. X., and Perucho, M. Comparative analysis of mutations in the p53 and K-ras genes in pancreatic cancer. Int. J. Cancer, 58: 185-191, 1994.
27. Smit, V. T., Boot, A. J., Smits, A. M., Fleuren, G. J., Cornelisse, C. J., and Bos, J. L. KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acids Res., 16: 7773-7782, 1988.
28. Tominaga S. Epidemiology of pancreatic cancer. Jpn. J. Cancer Chemother. (in Japanese), 19: 2297-2303, 1992.
29. Castells, A., Puig, P., Mora, J., Boadas, J., Boix, L., Urgell, E., Sole, M., Capella, G., Lluis F., Fernandez-Cruz, L., Navarro, S., and Farre, A. K-ras mutations in DNA extracted from the plasma of patients with pancreatic carcinoma: diagnostic utility and prognostic significance. J. Clin. Oncol., 17: 578-584, 1999.
30. Shiina, H., Igawa, M., Shigeno, K., Yamasaki, Y., Urakami, S., Yoneda, T., Wada, Y., Honda, S., and Nagasaki, M. Clinical significance of mdm2 and p53 expression in bladder cancer. Oncology, 56: 239-247, 1999.
31. Parada, L. F., Land, H., Weinberg, R. A., Wolf, D., and Rotter, V. Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation. Nature (Lond.), 312: 649-651, 1984.
32. Rozenblum, E., Schutte, M., Goggins, M., Hahn, S. A., Panzer, S., Zahurak, M., Goodman, S. N., Sohn, T. A., Hruban, R. H., Yeo, C. J., and Kern, S. E. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res., 57: 1731-1734, 1997.